This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Eargo Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Eargo is gedaald met een gemiddeld jaarlijks percentage van -35.8%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 13.1%. De inkomsten zijn daalde met een gemiddeld percentage van 2.6% per jaar.

Belangrijke informatie

-35.8%

Groei van de winst

83.6%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	-2.6%
Rendement op eigen vermogen	-239.7%
Nettomarge	-263.1%
Laatste winstupdate	30 Sep 2023

Recente prestatie-updates uit het verleden

Recent updates

Eargo: Straining To Be Heard

Aug 30

Eargo jumps 77% following FDA rule on OTC hearing aids

Aug 16

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Aug 08

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

Jul 10

Eargo: I Am Slowly Starting To Listen

May 06

What Kind Of Investors Own Most Of Eargo, Inc. (NASDAQ:EAR)?

Jan 16

Eargo trades high afte hours on strong Q4 revenue, gross systems shipped

Jan 11

Eargo: A Word Of Caution

Dec 15

Eargo beats on revenue

Nov 19

Opbrengsten en kosten

Hoe Eargo geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:EAR Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 23	41	-108	88	19
30 Jun 23	41	-141	94	19
31 Mar 23	40	-149	102	18
31 Dec 22	37	-157	107	19
30 Sep 22	34	-159	121	23
30 Jun 22	4	-188	139	25
31 Mar 22	19	-175	140	26
31 Dec 21	32	-158	136	25
30 Sep 21	44	-124	118	21
30 Jun 21	85	-45	94	17
31 Mar 21	79	-32	78	14
31 Dec 20	69	-30	70	12
30 Sep 20	57	-32	63	12
30 Jun 20	47	-44	59	12
31 Mar 20	38	-47	55	13
31 Dec 19	33	-44	48	13
30 Sep 19	30	-42	45	12
31 Dec 18	23	-34	34	10
31 Dec 17	7	-25	15	5

Kwaliteitswinsten: EAR is momenteel verliesgevend.

Groeiende winstmarge: EAR is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: EAR is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 35.8% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van EAR over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: EAR is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 12.2% ).

Rendement op eigen vermogen

Hoge ROE: EAR heeft een negatief Return on Equity ( -239.7% ), omdat het momenteel verliesgevend is.

This company has been acquired

Eargo Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Eargo, Inc. to Report Q1, 2023 Results on May 11, 2023

Third quarter 2022 earnings released: US$1.29 loss per share (vs US$2.02 loss in 3Q 2021)

Eargo, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Eargo, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Second quarter 2021 earnings released: US$0.50 loss per share (vs US$24.11 loss in 2Q 2020)

Recent updates

Eargo Files Form 15

Eargo, Inc.(NasdaqGS:EAR) dropped from NASDAQ Composite Index

Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

Eargo, Inc. Announces Chief Financial Officer Changes, Effective from January 5, 2024

Patient Square Capital, LP entered into an agreement to acquire remaining 23.8% stake in Eargo, Inc. (NasdaqGS:EAR) for $13 million.

Patient Square Capital, LP entered into an agreement to acquire remaining 23.8% stake in Eargo, Inc. (NasdaqGS:EAR) for $13 million.

Eargo, Inc. to Report Q1, 2023 Results on May 11, 2023

Nasdaq Confirms Eargo’s Minimum Bid Price Deficiency Is Cured

Hearing Wellness Pioneer Eargo Launches Eargo 7, Its Most Revolutionary Device Yet, at CES

Nasdaq Grants 180 Calendar Days to Eargo, Inc. to Regain Compliance

Less than half of directors are independent

Eargo, Inc. Announces Board Changes

Eargo, Inc. Announces the Appointment of Donald Spence to Its Board of Directors

Eargo, Inc. has completed a Follow-on Equity Offering in the amount of $187.5 million.

Independent Director exercised options to buy US$273k worth of stock.

Eargo Receives Non-Compliance Notice From Nasdaq

Eargo Receives a Non-Compliance Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC

Price target decreased to US$2.00

Third quarter 2022 earnings released: US$1.29 loss per share (vs US$2.02 loss in 3Q 2021)

Eargo, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Eargo: Straining To Be Heard

Eargo jumps 77% following FDA rule on OTC hearing aids

Price target decreased to US$2.00

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Eargo, Inc., Annual General Meeting, Oct 12, 2022

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Eargo, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Eargo completes $100M senior secured convertible notes issuance

Eargo, Inc.(NasdaqGS:EAR) dropped from Russell 2000 Growth Index

Eargo Receives a Letter from the Nasdaq Stock Market

Eargo Announces Receipt of Nasdaq Non-Compliance Letter

Eargo, Inc. announced delayed 10-Q filing

Eargo, Inc. announced delayed annual 10-K filing

Eargo, Inc. Launches Eargo 6 with Sound Adjust for Effortless Hearing

Eargo: A Binary Play On Hearing Loss

Price target decreased to US$10.50

Eargo Receives Notice from Nasdaq Stating Non Compliance with Listing Rule 5250(C)(1)

Eargo Is A High Risk 'Option' With High Potential

Eargo, Inc. Withdraws Financial Guidance for the Fiscal Year Ending December 31, 2021

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.50 loss per share (vs US$24.11 loss in 2Q 2020)

Eargo, Inc. Provides Financial Guidance for the Year 2021

Independent Director Geoffrey Pardo has left the company

Eargo Launches Eargo 5 Hearing Aid with Sound Match™ Technology

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

Chief Financial Officer notifies of intention to sell stock

Eargo, Inc.(NasdaqGS:EAR) dropped from Russell 3000E Value Index

Independent Director Juliet Bakker has left the company

Consensus EPS estimates increase to -US$1.00

First quarter 2021 earnings released: US$3.56 loss per share (vs US$33.52 loss in 1Q 2020)

Eargo, Inc. Increases Earnings Guidance for Full Year 2021

Eargo: I Am Slowly Starting To Listen

Independent Director notifies of intention to sell stock

Full year 2020 earnings released: US$3.80 loss per share (vs US$57.82 loss in FY 2019)

Analysts update estimates

Revenue and earnings beat expectations

Full year 2020 earnings released: US$3.80 loss per share (vs US$57.82 loss in FY 2019)

Analysts update estimates

Eargo, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: US$70.31

New 90-day high: US$63.00

What Kind Of Investors Own Most Of Eargo, Inc. (NASDAQ:EAR)?

Eargo trades high afte hours on strong Q4 revenue, gross systems shipped

Eargo: A Word Of Caution

Third quarter 2020 earnings released: US$24.38 loss per share

Eargo, Inc. Provides Earnings Guidance for the Full Year 2020

Eargo beats on revenue